Rituximab-induced lung disease.

Rituximab-induced lung disease: A systematic literature review.

The anti-CD20 antibody rituximab has been reported to induce a heterogeneous spectrum of lung disorders. The aim of the present study was to critically review data on the clinical presentations, causality assessments and management strategies of lung diseases possibly related to rituximab. A systematic literature review was performed on English-language reports in PubMed until September 2008. C...

Rituximab-Induced Bronchiolitis Obliterans Organizing Pneumonia

Rituximab-induced lung disease (R-ILD) is a rare entity that should be considered in patients treated with rituximab who present with dyspnea, fever, and cough, but no clear evidence of infection. A variety of pathologic findings have been described in this setting. Bronchiolitis obliterans organizing pneumonia (BOOP) is the most common clinicopathologic diagnosis, followed by interstitial pneu...

Refractory antisynthetase syndrome controlled successfully with ongoing rituximab therapy

We present a case of refractory anti-synthetase syndrome with myositis and interstitial lung disease that progressed despite multiple immunosuppressive therapies. We were able to control the disease with repeated courses of rituximab, achieving a sustained clinical response and stabilisation of disease progression. There is limited evidence for the use of rituximab in this disease and this case...

Standard Operating Procedure: Clinical Commissioning Policy: Rituximab for connective tissue disease associated with interstitial lung disease

Wegener's granulomatosis effectively treated with rituximab: a case study.

Wegener's granulomatosis (WG) is a granulomatous disorder associated with systemic necrotizing vasculitis. Wegener's granulomatosis predominantly involves the upper airways, lung and kidneys. The disease is often associated with cytoplasmic antineutrophil cytoplasmic antibodies (cANCA). B lymphocytes are potential cANCA producers and there is an evident correlation between cANCA titre, severity...